These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23912384)

  • 1. The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer.
    Crook J
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):258-64. PubMed ID: 23912384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.
    Bruchovsky N; Klotz L; Crook J; Phillips N; Abersbach J; Goldenberg SL
    Clin Genitourin Cancer; 2008 Mar; 6(1):46-52. PubMed ID: 18501083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
    Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intermittent androgen deprivation in advanced prostate cancer: a review].
    Wolff JM
    Aktuelle Urol; 2012 Mar; 43(2):115-20. PubMed ID: 22222751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Kratiras Z; Konstantinidis C; Skriapas K
    Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
    Seruga B; Tannock IF
    Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
    JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
    Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
    Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
    Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen suppression in prostate cancer: the Canadian experience.
    Hurtado-Coll A; Goldenberg SL; Gleave ME; Klotz L
    Urology; 2002 Sep; 60(3 Suppl 1):52-6; discussion 56. PubMed ID: 12231049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
    Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
    Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.
    Tunn U
    BJU Int; 2007 Jan; 99 Suppl 1():19-22; discussion 23-4. PubMed ID: 17229164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.